Nobody Monitors the FDA for Your Specific Products. We Built the Thing That Does.
MoCRA renewals, PFAS evaluations, warning letters up 73%. The information is public. The question is whether you know which of YOUR products any of it affects. That cross-reference step is where warning letters live — and nobody automates it. Until now.
By July 1, 2026, every cosmetics facility registered under MoCRA must complete its first FDA registration renewal — roughly 9,500 facilities, navigating the biggest expansion of FDA cosmetics authority since 1938.
But the renewal deadline isn't the real problem.
On December 29, 2025, the FDA released a PFAS safety evaluation identifying 51 per- and polyfluoroalkyl substances across 1,744 cosmetic formulations. The GMP regulations that were supposed to be final by December 2024 remain on the FDA's "long-term actions" list — indefinitely delayed. And in the second half of 2025, the FDA issued 73% more warning letters than the same period the year before.
If you run a cosmetics brand, do you know whether your moisturizer contains one of those 51 PFAS? Do you know what GMP standard your contract manufacturer should be meeting — when the FDA hasn't finalized one?
MoCRA is just one of the regulatory changes hitting food, supplement, and cosmetics brands right now. The FDA lost 3,859 employees in 2025. 140+ food additive bills are moving across 38 states. Red No. 3 authorization in food has been revoked — reformulation deadline January 15, 2027. The information is public. The question is whether you know which of your products any of it affects.
The Problem Isn't Information. It's the Mapping Step.
The Federal Register is free. Warning letters are public. The information exists.
The problem is what happens after you read it. Red No. 3 is being pulled from food products by January 15, 2027. Which of your 23 products contain it? At what levels? Do you need to reformulate? What happens if you don't?
That cross-reference step — from "the FDA did something" to "which of MY products are affected" — is manual, error-prone, and repeats for every single regulatory change. It takes hours. And it's the step that determines whether a regulatory change becomes a warning letter or a non-event.
You can get this intelligence from a regulatory consultant at $150–$500/hour, after the fact. Or from a newsletter that will never name your specific product. Nobody does the mapping step automatically. Nobody monitors the FDA for your specific products — by name, by ingredient.
“Supplement brands should watch this space. The FDA is evolving its position on identity testing requirements.”
“Your Marine Collagen Powder is affected. The FDA cited identity testing failures for marine-sourced collagen. Here are your 3 action items.”
What Product-Level Monitoring Looks Like
You tell us your products. We watch the FDA — proposed rules, final rules, warning letters, guidance documents, recalls, safety alerts, state-level changes.
When something changes that affects one of your specific products, we tell you the same day: which product, which ingredient, why it matters, what the deadline is, what to do next. When nothing changes, we tell you that too. "All clear — nothing affecting your products this week." That confirmation is part of the intelligence.
Here's What a Product Intelligence Alert Looks Like
Say you have Marine Collagen Powder in your account — a supplement with marine collagen, vitamin C, and hyaluronic acid.
The FDA issues a warning letter citing identity testing failures on marine-sourced collagen. Here's a constructed example based on real enforcement patterns in marine collagen identity testing:
YOUR PRODUCT IS AFFECTED: Marine Collagen Powder
What happened: FDA warning letter for identity testing failures on marine-sourced collagen under 21 CFR 111.75(a)(1)(ii). Third marine collagen-related enforcement action in 12 months.
Why this affects your product: Marine Collagen Powder lists marine collagen as its primary ingredient. The enforcement pattern indicates the FDA is prioritizing identity testing for marine-sourced collagen.
Action items:
- Verify your supplier provides a Certificate of Analysis with species-specific identity testing
- Confirm your lab's identity method distinguishes marine collagen from bovine/porcine sources
- Document your identity testing protocol in your batch records
Deadline: No formal compliance deadline. The enforcement pattern suggests active inspection priority — we recommend reviewing testing protocols this quarter.
Source: FDA Warning Letter · 21 CFR 111.75(a)(1)(ii)
If you don't sell marine collagen products, you wouldn't receive this alert. Because it doesn't affect your products.
That's the difference between a newsletter and intelligence.
The Math
One FDA warning letter costs $25,000–$100,000+ in direct response costs. Policy Canary starts at $99/month. The 14-day trial is free.
If the monitoring catches one issue before it becomes a warning letter, the subscription paid for itself before the first renewal.
Judge Us by the Work
We publish regulatory analysis on this blog every week. The same kind of sourced, product-specific analysis you just read. See if it's worth your time. If the analysis is good, you'll know.